Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

11.05 +0.05 (+0.50%)
Streaming Delayed Price Updated: 11:33 AM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Where Roivant Sciences Stands With Analysts
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
Via Benzinga
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Via Benzinga
Analyst Ratings for Roivant Sciences
Via Benzinga
8 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
What 8 Analyst Ratings Have To Say About Roivant Sciences
Via Benzinga
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in  
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)  
Via Benzinga
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV. 
Via InvestorPlace
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
PINS Stock Pops as Stifel Upgrades Pinterest
Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target. 
Via InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set... 
Via Benzinga
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
3 No-Brainer Growth Stocks to Buy in October
These three top mid-cap stocks could be poised for a long-tailed growth spurt. 
Via The Motley Fool
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion. 
Via Talk Markets
Why Shares of Immunovant Are Soaring on Tuesday
Immunovant sees strong potential for an autoimmune disorder therapy. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.